Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
fda
3
×
galcanezumab
3
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
calcitonin gene-related peptide
eptinezumab
erenumab
fremanezumab
lasmiditan
migraine
migraine research foundation
teva pharmaceutical
What
approval
class
companies
drug
fda
migraine
new
won
amgen
arena’s
arguments
big
bio
bounty
candidates
cig
comeback
commercialized
competitors
corner
deals
decades
delivered
developed
drugs
expressing
gets
head
ipo
life
little
make
medicines
meeting
moderna’s
neuro
nod
number
oral
pain
Language
Current search:
galcanezumab
×
fda
×
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
